健脾抑瘤汤治疗晚期原发性肝癌30例临床观察

Clinical Observation of 30 Cases of Late-Stage Primary Hepatic Cancer Treated with Jianpi Yiliu Decoction

目的观察健脾抑瘤汤治疗晚期原发性肝癌的临床疗效。方法将60例晚期原发性肝癌患者随机分成治疗组30例与对照组30例,两组患者采用相同的西药疗法,治疗组同时加用健脾抑瘤汤治疗,30 d为1个疗程,2个疗程后评价疗效。观察两组治疗后临床疗效、中医证候积分、生活质量积分、KPS评分和不良反应情况。结果治疗组与对照组总改善率分别为83.3%和60.0%(P<0.05);治疗组治疗后中医证候积分、生活质量积分和KPS评分均有改善,与本组治疗前和对照组治疗后比较,差异有统计学意义(P<0.05);对照组治疗后生活质量积分、KPS评分降低,与本组治疗前比较差异均有统计学意义(P<0.05)。两组不良反应比较,治疗组明显低于对照组(P<0.05)。结论健脾抑瘤汤治疗晚期原发性肝癌可以改善临床症状及机体免疫功能,提高生活质量,延长生存期。

Objective To observe the clinical efficacy on late - stage primary hepatic cancer（PHC） treated with jianpi yiliu decoction. Methods Sixty cases of late - stage PHC were randomized into a treat- ment group（30 cases）and a control group（30 cases）. The same therapy of western medicine was applied for the patients in the two groups. In the treatment group,jianpi yiliu decoction was supplemented. The treatment of 30 days made 1 session. The efficacy was evaluated in 2 sessions of treatment. The clinical efficacy, the in- tegral of Chinese medicine syndrome, the integral of living quality, KPS score and adverse reaction after treat- ment were observed in the two groups. Results The total improvement rates were 83.3% and 60.0% in the treatment group and the control group respectively （ P 〈 0.05 ）. The integral of Chinese medicine syndrome, the integral of living quality and KPS score were all improved after treatment in the treatment group, presen- ting the significant difference as compared with those before treatment in the same group and those after treat- ment in the control group（P 〈0.05）. The integral of living quality and KPS score were reduced after treat- ment in the control group, presenting the significant difference as compared with those before treatment in the same group（ P 〈 0.05 ）. In comparison of adverse reaction between the two groups ,the result in the treatment group was lower apparently than that in the control group（ P 〈 0.05 ）. Conclusion Jianpi yiliu decoction re- lieves the clinical symptoms, improves the body immune function and living quality and prolongs the life span for the patients of late - stage PHC.